TB-500 for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

TB-500 for Health & Longevity

Created on 08/07/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A laboratory-made copy of part of a natural repair protein. No completed human trial of the fragment exists; animal tendon work is the strongest signal, while heart, hair, nerve and aging claims rest on the parent molecule. Products sold online have not matched their labels, it is banned in organized sport, and long-term safety is unmeasured. (Full Review)

Protocol

The prevailing gray-market protocol
2–2.5 mg twice weekly
Subcutaneous; 4–6 weeks loading, then 2–2.5 mg weekly or every 2 weeks, or 0.03 mg/kg. Convention, not a validated regimen.
Local versus systemic injection
Systemic subcutaneous
No comparative data. The animal tendon studies used systemic administration, which argues local placement is not required.
Best time of day
Morning
No chronobiology data. Convention is morning dosing, so lethargy and any first-dose reaction fall in waking hours.
Time to effect
First perceptible change
2–4 weeks
Expected during loading; never measured in a human trial. Change within days is more plausibly anti-inflammatory.
Fuller effect
6–8 weeks
Animal tendon data assessed improvement after four weeks of treatment: consistent, but not confirmation.
Assessment at the end of a course
4–6 weeks after stopping
Real repair should hold after cessation. Improvement lost within days points to an expectation effect.

Benefits

Contraindications
  • Malignancy, active or treated within 5 years; anti-angiogenic therapy
  • Proliferative diabetic retinopathy, wet macular degeneration, other retinal neovascular disease
  • Competitive athletes under anti-doping rules (collegiate, professional, Olympic-pathway, masters); military personnel
  • Pregnancy, breastfeeding, or trying to conceive
  • eGFR < 30 mL/min/1.73 m², end-stage kidney disease, or Child-Pugh B/C liver impairment
  • Within 6 months of acute coronary syndrome or stroke; NYHA class III–IV heart failure
  • No independent third-party batch verification
    •
Key Interactions
  • Anticoagulants, antiplatelets (warfarin, apixaban, clopidogrel, aspirin)
  • Corticosteroids and immunosuppressants (prednisone, methotrexate, tacrolimus, adalimumab)
  • Anti-inflammatories (ibuprofen, naproxen, aspirin)
  • Stimulants (pseudoephedrine, high-dose caffeine)
  • Angiogenic supplements (arginine, citrulline, deer antler velvet, colostrum, GHK-Cu)
  • Bleeding-risk supplements (fish oil, Ginkgo, vitamin E > 400 IU, nattokinase, garlic)
  • Opposing agents (high-dose curcumin, high-dose green tea catechins, resveratrol)
  • Other interventions (BPC-157, platelet-rich plasma, corticosteroid joint injections, surgery)

Risk & Side Effects

  • High: Adulterated or mislabeled product; anti-doping sanction for athletes; absence of human safety data
  • Medium: Injection-site reactions and post-injection malaise; loss of legal access and regulatory enforcement
  • Low: Immunogenicity and loss of response; sterile abscess and injection-related infection
  • Speculative: Occult tumor growth or metastasis; accelerated plaque angiogenesis; bidirectional effects on fibrosis; endocrine or immune disruption from chronic dosing

Monitoring

Marker Target Why
hs-CRP < 0.5 mg/L Baseline inflammatory load; occult infection
Complete blood count with differential Neutrophils 1.8–5.0, lymphocytes 1.5–3.0, platelets 175–350 × 10⁹/L Marrow, immune, or infectious change under a proliferative signal
Creatinine and eGFR eGFR > 90 mL/min/1.73 m²; creatinine mid-range Renal clearance; screens a contraindication
ALT and AST ALT 10–26 (men), 8–22 (women); AST 10–26 U/L Organ-safety reference baseline
Fasting glucose and HbA1c Glucose 75–85 mg/dL; HbA1c 4.8–5.3% Hyperglycemia impairs angiogenesis and healing
PSA (men over 45) < 1.0 ng/mL at 40–50, age-adjusted after; velocity < 0.35/yr Prostate surveillance before a pro-migratory signal
Ferritin and iron saturation Ferritin 50–150 ng/mL; sat 25–35% Iron deficiency impairs collagen synthesis

Cadence: Baseline before the first dose, at 6 weeks, and 8–12 weeks after the course ends; annually for anyone cycling more than once a year. Cancer screening stays on its normal schedule.

Qualitative Assessment

  • Pain at a defined provocative movement, rated 0–10 on the same movement each time
  • Load tolerance, the weight or duration at which the injured tissue becomes symptomatic
  • Range of motion at the affected joint, by photograph or goniometer rather than impression
  • Morning stiffness duration, in minutes, which typically shortens before pain scores move
  • Sleep quality and daytime energy, to detect the post-dose lethargy some users report
  • Injection-site appearance at 24 hours: redness, induration, or warmth suggesting a contaminated batch
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.